3 days popular7 days popular1 month popular3 months popular

New Delivery Method Makes Targeted Gene Silencing Drugs More Than 500 Times More Effective

(siRNAs) are a potent new drug class that can silence a disease-causing gene, but delivering them to a target cell can be challenging. An innovative delivery approach that dramatically increases the efficacy of an siRNA drug targeted to the liver and has made it possible to test the drug in non-human primates is described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from , Inc. publishers. The article is available on the Nucleic Acid Therapeutics website.*

In the article “Co-Injection of a Targeted, Reversibly Masked Endosomolytic Polymer Dramatically Improves the Efficacy of Cholesterol-Conjugated Small Interfering RNAs In Vivo.” * Wong and colleagues from (Madison, WI) presented a novel strategy to overcome the difficulty in delivering high levels of a gene knockdown siRNA drug to liver cells. While the cholesterol-conjugated siRNA drug is taken up preferentially by the liver, it is encapsulated in membrane-bound globules called endosomes and cannot reach the cells’ DNA to exert its gene silencing effect. The researchers co-injected a polymer with the drug that also targets the liver and, once inside liver cells, breaks open the endosomes, releasing the siRNA drug.

“The promise of siRNAs is as strong as ever and is becoming even more so with progress in delivering these molecules to the right place at the right time,” says Executive Editor Fintan Steele, PhD, , Inc., Boulder, CO. “The work by Wong and colleagues is another important step towards realizing this promise.”


* http://www.liebertpub.com/nat

** http://online.liebertpub.com/doi/full/10.1089/nat.2012.0389

Nucleic Acid Therapeutics is under the editorial leadership of Co-Editors-in-Chief Bruce A. Sullenger, PhD, , DukeUniversity Medical Center, Durham, NC, and C.A. Stein, MD, PhD, City of Hope National Medical Center, Duarte, CA; and Executive Editor Fintan Steele, PhD, SomaLogic, Boulder, CO.

Mary Ann Liebert, Inc./Genetic Engineering News